Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
REGN-13335 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
REGN-13335: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
GT-02037 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
GT-02037: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ALZ-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ALZ-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ASC-41 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ASC-41: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
I001-B Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
I001-B: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
H7N9 Influenza Vaccine (Split Virion),Inactivated(Hualan Biological Bacterin) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
H7N9 Influenza Vaccine (Split Virion),Inactivated(Hualan Biological Bacterin): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development
9 min read
YN-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
YN-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Recombinant anti-IL-4Rα nanobody(Shanghai Novamab Biopharmaceuticals) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Recombinant anti-IL-4Rα nanobody(Shanghai Novamab Biopharmaceuticals): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, li
9 min read
GRF312 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
GRF312: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
NBI-1117567 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
NBI-1117567: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Codivir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Codivir: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PHN013 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
PHN013: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.